Education provider Globis closed its seventh VC fund at $543m while Heritage Medical Systems, Exor and Alexandria participated in RNA drug developer Orbital’s $270m series A round.
Fund
Globis Capital Partners, the corporate venturing arm of Japanese education services provider Globis, reached a $543m final close for its seventh fund, which is targeting domestic companies looking to disrupt traditional industries and expand outside Japan. The unit has also launched an office in San Francisco to help portfolio companies increase their presence in the United States.
Funding
US-based RNA medicine developer Orbital Therapeutics raised $270m in series A funding from investors including health insurer Heritage Medical Systems, diversified holding group Exor and Alexandria Venture Investments, part of life sciences property investment trust Alexandria Real Estate Equities. The round was led by Arch Venture Partners and also backed by Andreessen Horowitz’s Bio + Health unit, Newpath Partners, Abu Dhabi Growth Fund, Redmile Group, Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group,…
